1
|
Boriani G, Diemberger I, Biffi M, Martignani C, Ziacchi M, Bertini M, Valzania C, Bronzetti G, Rapezzi C, Branzi A. How, why, and when may atrial defibrillation find a specific role in implantable devices? A clinical viewpoint. PACING AND CLINICAL ELECTROPHYSIOLOGY: PACE 2007; 30:422-33. [PMID: 17367364 DOI: 10.1111/j.1540-8159.2007.00685.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
This viewpoint article discusses the potential for incorporation of atrial defibrillation capabilities in modern multi-chamber devices. In the late 1990s, the possibility of using shock-only therapy to treat selected patients with recurrent atrial fibrillation (AF) was explored in the context of the stand-alone atrial defibrillator. The failure of this strategy can be attributed to the technical limitations of the stand-alone device, low tolerance of atrial shocks, difficulties in patient selection, a lack of predictive knowledge about the evolution of AF, and, last but not least, commercial considerations. An open question is how atrial defibrillation capability may now assume a specific new role in devices implanted for sudden death prevention or cardiac resynchronization. For patients who already have indications for implantable devices, device-based atrial defibrillation appears attractive as a "backup" option for managing AF when preventive pharmacological/electrical measures fail. This and several other personalized hybrid therapeutic approaches await exploration, though assessment of their efficacy is methodologically challenging. Achievement of acceptance by patients is an essential premise for any updated atrial defibrillation strategy. Strategies that are being investigated to improve patient tolerance include waveform shaping, pharmacologic modulation of pain, and patient-activated defibrillation (patients might also perceive the problem of discomfort somewhat differently in the context of a backup therapy). The economic impact of implementing atrial defibrillation features in available devices is progressively decreasing, and financial feasibility need not be a major issue. Future studies should examine clinically relevant outcomes and not be limited (as occurred with stand-alone defibrillators) to technical or other soft endpoints.
Collapse
Affiliation(s)
- Giuseppe Boriani
- Institute of Cardiology, University of Bologna, Azienda Ospedaliera S. Orsola-Malpighi, Bologna, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Boriani G, Valzania C, Biffi M, Corazza I, Camanini C, Martignani C, Bacchi L, Zannoli R, Branzi A. Increase in QT/QTc dispersion after low energy cardioversion of chronic persistent atrial fibrillation. Int J Cardiol 2004; 95:245-50. [PMID: 15193827 DOI: 10.1016/j.ijcard.2003.05.022] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/13/2002] [Revised: 05/23/2003] [Accepted: 05/24/2003] [Indexed: 01/25/2023]
Abstract
BACKGROUND The effects of atrial internal cardioversion on QT interval and QT dispersion (parameters associated with increased risk of ventricular tachyarrhythmias) are unknown. We investigated changes in QT interval, QTc and QT dispersion immediately after shock delivery for internal cardioversion in patients with chronic persistent atrial fibrillation. METHOD Twenty-two patients with chronic persistent atrial fibrillation (mean duration, 17+/-23 months) underwent transvenous low-energy internal atrial cardioversion with a step-up protocol of shocks delivered between catheters in the right atrium and coronary sinus. (successful shock, 7.2+/-4.2 J). RR interval, QT interval, QTc interval, QT dispersion, and QTc dispersion were all measured on three consecutive beats (at 75 mm/s on at least 9 of 12 leads) and then averaged both before and after (1) the last unsuccessful shock, and (2) sinus rhythm restoration. RESULTS All parameters remained similar in the minute before and after the last unsuccessful shock. At 1 min after the successful shock, abrupt increases in QT dispersion (+43.8% vs. pre-shock; P<0.001 at least significant difference analysis) and QTc dispersion (+30.0%; P<0.05) were observed, followed by a gradual return to pre-shock values at 15 min. CONCLUSIONS These findings strongly suggest the likely existence of a brief period of increased electrical vulnerability immediately after restoration of sinus rhythm by internal cardioversion. Particular caution should therefore be applied whenever class III antiarrhythmic drugs are administered immediately after successful internal atrial cardioversion.
Collapse
Affiliation(s)
- Giuseppe Boriani
- Institute of Cardiology, University of Bologna, Policlinico S. Orsola via Massarenti n 9, 40138, Bologna, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Wolpert C, Jung W, Spehl S, Schimpf R, Omran H, Schumacher B, Esmailzadeh B, Tenzer D, Mehra R, Lüderitz B. Incidence and rate characteristics of atrial tachyarrhythmias in patients with a dual chamber defibrillator. Pacing Clin Electrophysiol 2003; 26:1691-8. [PMID: 12877702 DOI: 10.1046/j.1460-9592.2003.t01-1-00254.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Atrial tachyarrhythmias play an important role in the treatment of patients with malignant ventricular tachyarrhythmias not only with respect to inappropriate discharges but also to left ventricular function and stroke risk. A combined dual chamber defibrillator provides separate therapies for atrial and ventricular tachyarrhythmias. To assess the incidence of atrial tachyarrhythmias in patients with this dual chamber implantable defibrillator, 40 patients with ventricular tachyarrhythmias and concomitant atrial tachyarrhythmias and/or AV conduction disturbances were included in a prospective study. During a mean follow-up of 25 +/- 11 months, 26 of 40 patients had a total of 1,430 recurrences of atrial tachyarrhythmias. The vast majority of the atrial tachyarrhythmias with regular atrial cycles had a mean median atrial cycle length of 235 +/- 37 ms and a mean duration of 34 +/- 144 minutes. Atrial tachyarrhythmias with irregular atrial cycles exhibited a median atrial cycle length of 198 +/- 31 ms and had a mean duration of 246 +/- 1,264 minutes. In addition, 67% of 375 tachyarrhythmias, in which the median ventricular cycle length during the ongoing episode could be documented, had a ventricular rate <100 beats/min. Continuous atrial arrhythmia detection with a dual chamber ICD reveals a high incidence of atrial tachyarrhythmias with a predominantly short duration of paroxysmal recurrences <1 hour in the vast majority of episodes.
Collapse
|
4
|
Hynes BJ, Luck JC, Wolbrette DL, Bhatta L, Khan M, Samii S, Naccarelli GV. Atrial fibrillation in patients with heart failure. Curr Opin Cardiol 2003; 18:32-8. [PMID: 12496499 DOI: 10.1097/00001573-200301000-00005] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Atrial fibrillation and heart failure are very common cardiac disorders, and both are associated with symptoms, significant morbidity, and mortality. Studies have attempted to determine the prognostic significance of atrial fibrillation in patients with heart failure. Whether atrial fibrillation is an independent risk factor of mortality remains controversial. Multiple trials using either pharmacologic or nonpharmacologic therapies in an attempt to manage atrial fibrillation have been developed. The purposes of this review are to present an overview of atrial fibrillation in patients with heart failure and to discuss the prevalence, prognostic significance, complications, mechanisms, and trials that have formed the therapies presently used.
Collapse
Affiliation(s)
- B John Hynes
- Division of Cardiology, Penn State University College of Medicine, Hershey, PA 17033, USA
| | | | | | | | | | | | | |
Collapse
|
5
|
Boriani G, Biffi M, Camanini C, Sammali A, Bacchi L, Accorti P, Luceri R, Zannoli R, Branzi A. Transvenous internal cardioversion for atrial fibrillation: a randomized comparison between catheters with different coil length. Am Heart J 2002; 144:851-7. [PMID: 12422155 DOI: 10.1067/mhj.2002.125506] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJECTIVES The aim of this study was to evaluate the effects of 2 different right atrial electrode coil lengths on energy and voltage requirements for transvenous atrial cardioversion. METHODS Twenty-six patients (mean age 61 +/- 11 years) with chronic persistent atrial fibrillation (AF) (mean duration 11 +/- 10 months) underwent transvenous cardioversion. A 6F catheter with a 5.5-cm coil was positioned in the coronary sinus. Another catheter with either a 5.5-cm or an 8-cm coil was positioned along the lateral wall of the right atrium, according to a randomized allocation. R wave-synchronized biphasic shocks were delivered according to a step-up protocol. After cardioversion of baseline AF, AF was reinduced, the right atrial catheter was substituted, and cardioversion was repeated with the alternative right atrial coil. RESULTS Successful cardioversion was obtained in all of the patients. Leading edge voltage of effective shocks was significantly lower when catheters with an 8-cm coil in right atrium were used compared with the alternative 5-cm coil catheters (301 +/- 80 volts vs 340 +/- 78 volts, P <.001), and delivered energy (6.75 +/- 4.25 joules vs 7.86 +/- 4.29 joules, P =.043) and shock impedance (60 +/- 9 ohm vs 66 +/- 10 ohm, P <.001) were lower. Moreover, shock-induced discomfort, evaluated by assessment of pain score, was reduced (3.69 +/- 1.09 vs 4.12 +/- 0.99, P =.035). CONCLUSIONS The use of a longer right atrial coil results in lower shock impedance, lower energy and voltage requirements, and lower discomfort during transvenous atrial cardioversion. The results of the current study are of value either for transvenous internal cardioversion of chronic persistent AF or for implantable atrial defibrillators.
Collapse
Affiliation(s)
- Giuseppe Boriani
- Institute of Cardiology, University of Bologna, Azienda Ospedaliera S. Orsola-Malpighi, Bologna, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
McCabe PJ, Geoffroy S. Atrial fibrillation: the newest frontier in arrhythmia management. PROGRESS IN CARDIOVASCULAR NURSING 2002; 17:110-23, 141. [PMID: 12091760 DOI: 10.1111/j.0889-7204.2002.01450.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
At least 2.3 million people in the United States have atrial fibrillation. Since the risk for developing atrial fibrillation increases with age, the number of people with atrial fibrillation is expected to rise sharply. Atrial fibrillation is a complex condition that adversely influences mortality, morbidity, quality of life, and use of health care resources. Knowledge generated from extensive research has led to innovative management strategies. As the number of individuals with atrial fibrillation increases and treatment options expand, nurses in a variety of settings will be challenged to respond to the multifaceted needs of this population. This review discusses the significance of atrial fibrillation and summarizes research findings influencing current management strategies. Pharmacologic therapies are reviewed and new technologies for atrial fibrillation treatment are introduced. Nursing assessment and treatment of patients' response to atrial fibrillation are discussed. Recommendations for patient education are offered. A plan describing specific nursing diagnoses, outcomes, interventions, and activities for care of patients with atrial fibrillation is presented.
Collapse
Affiliation(s)
- Pamela J McCabe
- Department of Nursing, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
| | | |
Collapse
|
7
|
Naccarelli GV, Hynes J, Wolbrette DL, Bhatta L, Khan M, Luck J. Maintaining stability of sinus rhythm in atrial fibrillation: antiarrhythmic drugs versus ablation. Curr Cardiol Rep 2002; 4:418-25. [PMID: 12169239 DOI: 10.1007/s11886-002-0042-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
In managing atrial fibrillation, the main therapeutic strategies include rate control, termination of the arrhythmia, and pr vention of recurrences and thromboembolic events. Rate control with digoxin, b-blockers, verapamil, and diltiazem may be preferred in drug refractory and sedentary patients with markedly dilated left atrium and atrial fibrillation of long duration. Drugs useful in the maintenance of sinus rhythm include quinidine, procainamide, disopyramide, sotalol, amiodarone, dofetilide, flecainide, and propafenone. In patients with structural heart disease, the class III antiarrhythmics are the initial drugs of choice, given their neutral effects on survival in a post-myocardial infarction and congestive heart failure population. Due to high recurrence rates with pharmacologic therapy, nonpharmacologic options of therapy include atrioventricular junction ablation, atrial defibrillators, catheter ablation of pulmonary vein foci, and attempts to perform an atrial Maze procedure using catheters. Hybrid therapy using drugs in combination with nonpharmacologic approaches will be used more frequently in the future for refractory patients.
Collapse
Affiliation(s)
- Gerald V Naccarelli
- Hershey Medical Center, Division of Cardiology, 500 University Drive, Hershey, PA 17033, USA.
| | | | | | | | | | | |
Collapse
|
8
|
Boriani G, Biffi M, Martignani C, Luceri R, Bartolini P, Branzi A. Current clinical perspectives on implantable devices for atrial defibrillation. Curr Opin Cardiol 2002; 17:82-9. [PMID: 11790938 DOI: 10.1097/00001573-200201000-00012] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
The role of devices that deliver shock therapy for atrial fibrillation is still debated. Following technical improvements in catheter-based atrial defibrillation, implantable devices have become available either in the form of stand-alone atrial defibrillators or in the form of dual defibrillators. Although preliminary results do not support their use as a single, unique treatment for atrial fibrillation patients, in combination with drugs, pacing or other treatments such as ablation, atrial defibrillators should help appropriately selected groups of patients.
Collapse
|
9
|
Boriani G, Biffi M, Renzi R, Capestro F, Pierantozzi A, Sgarbi E, Scarfó S, Alboni P, Migani L, Sallusti L, Frabetti L, Branzi A. A semi-automatic algorithm for reducing the time spent on routine follow-up of cardioverter defibrillators. Int J Artif Organs 2001. [DOI: 10.1177/039139880102400305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background The routine follow-up of cardioverter defibrillators (CD) is a time-consuming procedure. Aim of the Study and Methods The present study was a prospective randomized cross-over evaluation on the clinical usefulness of a specific semi-automatic software algorithm (Quick Check) for CD follow-up, available in CPI Guidant systems (CD and programmer). Time-saving, while ensuring all the required data and patient safety, was evaluated in a large group of patients (105), recruited in different centers. In the same session and under a physician's supervision all patients underwent a follow-up with the aid of Quick Check or a standard follow-up, in a randomized sequence. Each patient served as his own control. Results In the overall population of 105 patients, the time spent for follow-up was reduced by Quick Check from 186±105 sec to 106±67 sec (p<0.0001) (43% reduction). The reduction in time spent for follow-up with Quick Check was the same (43% reduction) in patients with detected episodes (n=38) (from 241±144 sec to 138±95 sec (p<0.0001)) and in patients without detected episodes (n=67) (from 154±52 sec to 88±34 sec (p<0.0001)). No adverse events or deletion of potentially useful data was detected by the supervising physician. Conclusions Use of a specific software algorithm for routine follow-up of implanted CDs allows a significant shortening of the time spent on routine follow-up, thus reducing costs. The supervision of a physician is a guarantee of patient safety.
Collapse
Affiliation(s)
- G. Boriani
- Institute of Cardiology, University of Bologna, and Departments of Cardiology, Milano - Italy
| | - M. Biffi
- Institute of Cardiology, University of Bologna, and Departments of Cardiology, Milano - Italy
| | - R. Renzi
- Hospitals of Ancona, Milano - Italy
| | | | | | | | | | | | - L. Migani
- Hospitals of Guidant Italia, Milano - Italy
| | | | - L. Frabetti
- Institute of Cardiology, University of Bologna, and Departments of Cardiology, Milano - Italy
| | - A. Branzi
- Institute of Cardiology, University of Bologna, and Departments of Cardiology, Milano - Italy
| |
Collapse
|
10
|
Abstract
This review focuses on the important role played by the various types of remedial therapy in the prevention and treatment of perioperative cardiac arrhythmias. It discusses the new concepts of arrhythmogenesis and pro-arrhythmia; the long QT interval syndrome; newer, more selective class 3 antiarrhythmic drugs; cardiac rhythm management devices; drugs or devices used as prophylaxis for postoperative atrial arrhythmias; intravenous amiodarone for destabilizing ventricular arrhythmias; and preoperative potassium imbalance.
Collapse
Affiliation(s)
- J L Atlee
- Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA.
| |
Collapse
|
11
|
Friedman PA, Glikson M, Stanton MS. Defibrillator challenges for the new millennium: the marriage of device and patient-making and maintaining a good match. J Cardiovasc Electrophysiol 2000; 11:697-709. [PMID: 10868745 DOI: 10.1111/j.1540-8167.2000.tb00034.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Although it has become clear that implantable cardioverter defibrillators (ICDs) are effective, important challenges remain for the physician. Due to the limitations of available risk stratification tools, patient selection for primary sudden death prevention remains controversial in many populations. Additionally, the proliferation of device choices has led to challenges in matching the appropriate device to the individual patient: device size is balanced against longevity; the advantages of dual chamber systems is weighed against their increased complexity; physician and patient preferences in device implant site are constrained by site-dependent effects on defibrillation effectiveness and lead failure rates; and special consideration must be given to the patient with a preexisting pacemaker. After ICD placement, determination of appropriate follow-up frequency and methodology to assess device function must be considered. This article will review patient selection, device implant site selection, device-device interactions, single versus dual chamber ICD selection, and follow-up.
Collapse
Affiliation(s)
- P A Friedman
- Division of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
| | | | | |
Collapse
|
12
|
Morris MM, KenKnight BH, Warren JA, Lang DJ. A preview of implantable cardioverter defibrillator systems in the next millennium: an integrative cardiac rhythm management approach. Am J Cardiol 1999; 83:48D-54D. [PMID: 10089840 DOI: 10.1016/s0002-9149(98)01005-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The implantable cardioverter defibrillator (ICD), a primary therapeutic option for preventing sudden cardiac death, has rapidly evolved since being introduced clinically in 1980. Technologic advances in several key areas have enabled ICDs to provide more sophisticated rhythm management. Recent emphasis has been placed on dual-chamber ICDs possessing adaptive-rate pacing capabilities. Adoption of dual-chamber ICD systems has been rapid. The capabilities of future ICD systems will be governed by an integrative strategy that brings together sets of features specifically targeted at multifaceted rhythm disorders. The addition of atrial therapy will require more sophisticated rhythm discrimination algorithms. ICD technology will improve on several fronts including leads, integrated circuits, batteries, and capacitors. Additionally, state-of-the-art pacemaker technology will continue to be incorporated into ICDs. As these new ICD systems become increasingly sophisticated from an engineering viewpoint, tremendous emphasis will be placed on decreasing the complexity of programming, device interrogation, and patient monitoring during routine patient follow-up. Vast improvements in ICD programming systems may ultimately permit the 1-minute follow-up.
Collapse
Affiliation(s)
- M M Morris
- Therapy Research Department, Guidant CRM, St. Paul, Minnesota, USA
| | | | | | | |
Collapse
|